Relationship between anti-Xa level achieved with prophylactic low-molecular weight heparin and venous thromboembolism in trauma patients: A systematic review and meta-analysis
- 22 February 2022
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of Trauma and Acute Care Surgery
- Vol. 93 (2) , e61-e70
Abstract
BACKGROUND: Trauma patients have simultaneously high venous thromboembolism (VTE) and bleeding risk. Optimal chemoprophylaxis regimens remain unclear. This study aims to answer three questions for trauma patients. Is there any association between anti-Xa and VTE? Does dose adjustment improve prophylactic anti-Xa rates? Does dose adjustment improve anti-Xa adequacy and VTE compared with standard dosing? METHODS: Systematic search of MEDLINE, Embase, Scopus, and Web of Science occurred in May 2021. Two author reviews included trauma studies that evaluated low molecular weight heparin chemoprophylaxis, reported anti-Xa level, and evaluated more than one outcome. Data were dually extracted and estimated effects were calculated using RevMan 5.4 applying the Mantel-Haenszel method. Analysis 1 compared patients with peak anti-Xa of 0.2 IU/mL or greater or trough 0.1 IU/mL or greater to those with lower anti-Xa using VTE as the primary outcome. Analysis 2 reported the effect of dose adjustment on anti-Xa. Analysis 3 compared standard dosing to dose adjustment with the primary outcome being anti-Xa adequacy; secondary outcomes were VTE, pulmonary embolism, and bleeding complications. RESULTS: There were 3,401 studies evaluated with 24 being included (19 retrospective studies, 5 prospective studies). In analysis 1, achieving adequate anti-Xa was associated with reduced odds of VTE (4.0% to 3.1%; odds ratio [OR], 0.52; p = 0.03). Analysis 2 demonstrated that 768 (75.3%) patients achieved prophylactic anti-Xa with adjustment protocols. Analysis 3 suggested that dose-adjusted chemoprophylaxis achieves prophylactic anti-Xa more frequently (OR, 4.05; p = 0.007) but without VTE (OR, 0.72; p = 0.15) or pulmonary embolism (OR, 0.48; p = 0.10) differences. In subgroup analysis, anti-Xa dose adjustment also suggested no VTE reduction (OR, 0.68; p = 0.08). CONCLUSION: Patients with higher anti-Xa levels are less likely to experience VTE, and anti-Xa guided chemoprophylaxis increases anti-Xa adequacy. However, dose adjustment, including anti-Xa guided dosing, may not reduce VTE. LEVEL OF EVIDENCE: Systematic Review Meta-Analysis, Level IV.Keywords
This publication has 43 references indexed in Scilit:
- Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile rangeBMC Medical Research Methodology, 2014
- Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patientsJournal of Trauma and Acute Care Surgery, 2014
- Weight-based enoxaparin dosing for venous thromboembolism prophylaxis in the obese trauma patientThe American Journal of Surgery, 2013
- A comparative study of varying doses of enoxaparin for thromboprophylaxis in critically ill patients: a double-blinded, randomised controlled trialCritical Care, 2013
- A randomized, double-blinded, placebo-controlled pilot trial of anticoagulation in low-risk traumatic brain injuryJournal of Trauma and Acute Care Surgery, 2012
- Duplex ultrasound screening detects high rates of deep vein thromboses in critically ill trauma patientsJournal of Vascular Surgery, 2011
- Factors influencing enoxaparin anti-Xa activity in surgical critically ill patientsJournal of Critical Care, 2011
- Standard Prophylactic Enoxaparin Dosing Leads to Inadequate Anti-Xa Levels and Increased Deep Venous Thrombosis Rate in Critically Ill Trauma and Surgical PatientsJournal of Vascular Surgery, 2011
- Measuring inconsistency in meta-analysesBMJ, 2003
- Meta-analysis of Observational Studies in EpidemiologyA Proposal for ReportingJAMA, 2000